Adaptimmune Therapeutics PLC News Releases

Adaptimmune Announces Changes to Board and Executive Leadership Team

Mon, 17 Nov 2025 07:30:00 -0500

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025.Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company,...

Adaptimmune Announces Delisting from Nasdaq

Mon, 20 Oct 2025 07:40:00 -0400

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the...

Adaptimmune Reports Q2 Financial Results and Provides Business Update

Wed, 13 Aug 2025 07:30:00 -0400

Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone paymentsFollowing the transaction, Adaptimmune has repaid its debt and is restructuring to maximize value from remaining assets, including PRAME and CD70 directed T-cell therapiesPhiladelphia, Pennsylvania and Oxford,...

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Mon, 28 Jul 2025 07:30:00 -0400

Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price is $55m in cash to be paid upon consummation of the sale with up to $30m in potential future payments upon achievement of certain milestonesAdaptimmune will retain rights to its preclinical assets including PRAME, CD70, and its allogeneic program Adaptimmune will restructure to support the...

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Tue, 13 May 2025 07:30:00 -0400

TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026Adaptimmune had Total Liquidity1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune...

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Wed, 07 May 2025 12:00:00 -0400

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor...

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Thu, 20 Mar 2025 07:00:00 -0400

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder...

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Wed, 12 Mar 2025 16:54:00 -0400

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press...

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Thu, 30 Jan 2025 16:00:00 -0500

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.Guggenheim Securities SMID Cap Biotech Conference, New York, NYFireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. ESTWebcast link:...

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Mon, 13 Jan 2025 08:00:00 -0500

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assetsAdaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the Wuxi Global Forum 2025Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today...